These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8006130)

  • 41. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP).
    Lenton E; Soltan A; Hewitt J; Thomson A; Davies W; Ashraf N; Sharma V; Jenner L; Ledger W; McVeigh E
    Hum Reprod; 2000 May; 15(5):1021-7. PubMed ID: 10783345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles.
    Romeu A; Monzó A; Peiró T; Diez E; Peinado JA; Quintero LA
    J Assist Reprod Genet; 1997 Oct; 14(9):518-24. PubMed ID: 9401870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating inhibins and activin A during GnRH-analogue down-regulation and ovarian hyperstimulation with recombinant FSH for in-vitro fertilization-embryo transfer.
    Lockwood GM; Muttukrishna S; Groome NP; Knight PG; Ledger WL
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):741-8. PubMed ID: 9039341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization.
    Manau D; Fábregues F; Arroyo V; Jiménez W; Vanrell JA; Balasch J
    Fertil Steril; 2002 Dec; 78(6):1261-7. PubMed ID: 12477522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization.
    Neveu S; Hedon B; Bringer J; Chinchole JM; Arnal F; Humeau C; Cristol P; Viala JL
    Fertil Steril; 1987 Apr; 47(4):639-43. PubMed ID: 3106101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
    Ye H; Huang G; Pei L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer.
    Onagawa T; Shibahara H; Ayustawati ; Machida S; Hirano Y; Hirashima C; Takamizawa S; Suzuki M
    Gynecol Endocrinol; 2004 Jun; 18(6):335-40. PubMed ID: 15497496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The empty follicle syndrome: a pharmaceutical industry syndrome.
    Zegers-Hochschild F; Fernández E; Mackenna A; Fabres C; Altieri E; Lopez T
    Hum Reprod; 1995 Sep; 10(9):2262-5. PubMed ID: 8530648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF.
    Ravhon A; Lavery S; Michael S; Donaldson M; Margara R; Trew G; Winston R
    Hum Reprod; 2000 Nov; 15(11):2297-301. PubMed ID: 11056122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
    Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
    Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of a sustained release formulation of the gonadotrophin-releasing hormone agonist histrelin on serum concentrations of gonadotrophins and oestradiol, and ovarian LH/human chorionic gonadotrophin receptor content in the rat.
    Gunnet JW; Demarest KT; Hahn DW; Ericson E; McGuire JL
    J Endocrinol; 1991 Nov; 131(2):211-8. PubMed ID: 1744568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.
    Burgués S;
    Hum Reprod; 2001 Dec; 16(12):2525-32. PubMed ID: 11726569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.